



# FILE COPY

May 5, 2003

Nicholas M. Fleischer, R.Ph., Ph.D.  
Vice President  
Clinical Pharmacology & Biopharmaceutics  
The Weinberg Group Inc.  
1220 Nineteenth Street, N.W., Suite 300  
Washington, DC 20036-2400

Dear Dr. Fleischer:

Your petition requesting the Food and Drug Administration to declare that the drug product, Glyburide and Metformin HCl Tablets for Oral Solution, 1.25 mg/250 mg; 2.5 mg/500 mg; 5 mg/500 mg, is suitable for submission as an abbreviated new drug application was received by this office on 05/02/03. It was assigned docket number 03P-0188/CP 1 and it was filed on 05/05/03. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note that the acceptance of the petition for filing is a procedural matter in that it in no way reflects an agency decision on the substantive merits of the petition.

Sincerely,

Lyle D. Jaffe  
Dockets Management Branch

03P-0188

ACK 1